Health officials in Prince Edward Island are set to participate in a global research endeavor focused on enhancing stroke outcomes by optimizing the use of a blood-clot-dissolving medication for emergency stroke cases. Health P.E.I. is actively involved in the study, which aims to determine the most efficient dosage of Tenecteplase, a drug presently administered on the island.
Dr. Heather Williams, a neurologist and head of Health P.E.I.’s stroke steering committee, explained that the study seeks to evaluate if a lower dose of Tenecteplase can maintain efficacy in breaking up blood clots during a stroke while potentially reducing risks. Patients will be enrolled in the research through emergency departments, where eligible individuals receiving clot-busting treatment will be considered for inclusion in the trial.
The study will also explore the effectiveness of Tenecteplase for patients using blood thinners and the potential benefits of combining it with a neuro-protective drug named NoNO-42 to prevent brain cell damage. Dr. Williams highlighted the role of NoNO-42 in reducing the release of harmful toxins by stressed brain cells during a stroke, aiming to safeguard brain cell integrity until normal blood flow is restored.
Notably, NoNO-42 has connections to Prince Edward Island, with researchers from UPEI contributing to its development. Dr. Andrew Tasker, a neuropharmacology professor emeritus at UPEI’s Atlantic Veterinary College, expressed pride in their involvement and optimism for the drug’s impact on patients’ lives. While NoNO-42 is still undergoing trials, early results have been promising, suggesting potential benefits in increasing survival rates and post-stroke functional independence.
Dr. Williams emphasized the goal of achieving improved stroke outcomes through the combined use of these treatments, aiming for reduced disability, nursing home admissions, and stroke-related deaths. Approximately 15% of stroke patients in P.E.I. are eligible for Tenecteplase treatment, automatically enrolling them in the upcoming trial, slated to commence in the fall and span 12 to 18 months. Following data analysis, findings are expected to be released within the subsequent two years.